Whitehawk Therapeutics Reports Q3 2026 Results and Initiates Phase 1 Trial for HWK-206
The company reported $169.7 million in cash and announced the initiation of a Phase 1 trial for HWK-206 in SCLC with Fast Track designation from the FDA.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed